TY - JOUR
T1 - PD-Loma
T2 - a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
AU - Hirsch, Laure
AU - Zitvogel, Laurence
AU - Eggermont, Alexander
AU - Marabelle, Aurelien
N1 - Publisher Copyright:
© 2018, Cancer Research UK.
PY - 2019/1/8
Y1 - 2019/1/8
N2 - Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research strategies for the next generation of combination immunotherapy.
AB - Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research strategies for the next generation of combination immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85056303637&partnerID=8YFLogxK
U2 - 10.1038/s41416-018-0294-4
DO - 10.1038/s41416-018-0294-4
M3 - Editorial
C2 - 30413824
AN - SCOPUS:85056303637
SN - 0007-0920
VL - 120
SP - 3
EP - 5
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 1
ER -